Postsurgical tumor relapse was also further inhibited by immunotherapy of IL-6R in the shMCT-1 group (12.5%) than in the scramble group (77.8%) when compared with IgG2b, κ treatment of scramble (100%) and shMCT-1 (55.6%) cohorts (Figure 4C). The gene discussed is IL6R; the disease is neoplasm.